Bristol Myers Squibb
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 7 | 6 | scaled | 6 | 4 |
| Research labs and data | 2 | 2 | funded or contracted | 0 | 2 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Bristol Myers Squibb scores 7 out of 10 for priority and 6 out of 10 for delivery on AI in drug discovery, at the scaled stage. The company reports that all of its small molecule experiments and half of its large molecule experiments now use an AI model to predict their probability of success. On research labs and data it scores 2 out of 10 for priority and 2 out of 10 for delivery, at the funded or contracted stage, based on an enterprise agreement with Anthropic to deploy Claude across functions including research, linked to the systems that hold BMS scientific knowledge. Six AI in drug discovery commitments were made public in the last 12 months, against three in the year before, including an expansion of its NVIDIA DGX SuperPOD compute announced by BMS, agreements with Chai Discovery, Schrödinger and insitro, and the acquisition of Orbital Therapeutics; no research labs and data commitment was made public in either year. On 6 October 2026, four R&D roles were open in AI in drug discovery, in machine learning, research AI and computational science, and two in research labs and data, a discovery research IT analyst and a high-throughput biologics platform scientist.
AI in drug discovery
What the company says: Priority 7
Our focus on innovation includes leveraging data and integrating AI across the business to become a more efficient organization and accelerate the delivery of medicines to patients.
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of success
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
announced an expansion of its existing collaboration with NVIDIA to deploy NVIDIA's newest AI infrastructure, Vera Rubin NVL72, for running predictive models at scale ... design and test candidate molecules faster
Q2 2026 earnings press release, 30 Jul 2026, p. 5
Broaden AI application across R&D to optimize operations while improving quality & pace of innovation
Q1 2026 Results investor presentation, 30 Apr 2026, p. 6
we have taken steps to increase the probability of success in our clinical trials and are infusing artificial intelligence throughout our R&D process
Bristol Myers Squibb 2025 Form 10-K, 11 Feb 2026, p. 49
Infusing AI and technology into the process to move with greater speed and urgency
J.P. Morgan Healthcare Conference 2026 presentation, 12 Jan 2026, p. 8
Expanding AI to help teams move faster and operate more efficiently, further strengthened through our Anthropic & NVIDIA partnerships
Q2 2026 Results investor presentation, 30 Jul 2026, p. 6
For Mr. Meyers, in the role of Chief Digital & Technology Officer, the Committee considered his ... leadership in driving enterprise-wide adoption and implementation of artificial intelligence tools and technologies, directly impacting the discovery, development and delivery of medicines
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 73
What it shows running: Delivery 6, scaled
builds on nearly three years of collaboration that began when BMS first deployed NVIDIA DGX SuperPOD infrastructure to support its Research and Development activities
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of success
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
AI informs the design of every small molecule program and the majority of the company’s large molecule programs
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
A hundred percent of these small molecule degraders and LDDs are now being supported by what we call ... Predict First
Science Firsthand: advancing research in protein degradation with a unique approach, 27 Jan 2026
Over 90% of our small molecule and nearly 50% of large molecule experiments ... without an AI model predicting probability of success
AI agents that automate target identification and validation save BMS scientists weeks of manual work
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
This lets us direct resources to the most promising candidates, thereby reducing development time and associated costs.
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
Commitments made public in the last 12 months: 6
- AISB Bind federated binding-prediction initiative (Apheris): BMS is a founding partner in AISB Bind, a federated model for small-molecule binding prediction. New, announced, 22 Sep 2026. Published by: partner release, company quoted.
- Chai Discovery AI antibody discovery collaboration: BMS will use Chai Discovery AI folding and design models to discover antibody candidates. New, announced, 20 Aug 2026. Published by: partner only.
- Schrödinger Bunsen agentic AI co-scientist deployment: BMS agrees to deploy Schrödinger agentic AI co-scientist Bunsen in its research organisation. New, announced, 5 Aug 2026. Published by: media only.
- NVIDIA DGX SuperPOD AI factory for R&D (with Equinix-hosted infrastructure): BMS will expand compute with NVIDIA DGX Vera Rubin SuperPOD to scale proprietary discovery AI models. Expanded, announced, 20 Jul 2026. Published by: company.
- insitro ALS discovery collaboration: insitro and BMS extend their ALS collaboration for one year; insitro will use its ML ChemML platform to design molecules. Expanded, announced, 14 Oct 2025. Published by: joint release.
- Orbital Therapeutics acquisition (RNA platform with AI-driven design): BMS agrees to acquire Orbital, including its RNA platform that integrates AI-driven design. New, announced, 10 Oct 2025. Published by: joint release.
Commitments made public in the year before: 3
- AISB Network Federated OpenFold3 initiative (Apheris): BMS joins AISB Federated OpenFold3 Initiative to fine-tune OpenFold3 on proprietary structural data. New, announced, 1 Oct 2025. Published by: partner release, company quoted.
- OpenFold consortium membership: BMS joined the OpenFold consortium for open-source AI structural biology models. New, announced, 15 Apr 2025. Published by: joint release.
- Evotec protein degradation (molecular glue) partnership: Partnership expanded to molecular glue degraders beyond oncology, triggering a US$50m payment to Evotec. Expanded, announced, 23 Oct 2024. Published by: partner only.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Associate Director - Machine Learning Sciences, Cambridge Crossing - MA - US
- Principal Research AI Innovation Lead, Remote - United States - US
- Principal Scientist - Computational Sciences, San Diego - CA - US
- Principal Scientist, Computational Biology, Cambridge Crossing - MA - US
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 2
For Mr. Meyers, in the role of Chief Digital & Technology Officer, the Committee considered his: (i) leadership in driving transformation and innovation at scale across the business, and in simplifying and strengthening scientific and digital foundations
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 73
Connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS' scientific, clinical, regulatory, and commercial expertise resides
today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions
What it shows running: Delivery 2, funded or contracted
today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions
Connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS' scientific, clinical, regulatory, and commercial expertise resides
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Discovery Research Domain Analyst, IT Business Analyst, Princeton - NJ - US
- Senior Scientist, High-Throughput Biologics Production and Discovery Platforms, Brisbane - CA - US
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- Lab data and lab automation work sits in several units, including a Molecular Invention team building discovery data products and a Discovery Biotherapeutics team running high-throughput biologics production with lab automation. Who decides on ELN, LIMS, registration and scheduling software, and how do these teams connect to the compute BMS says will train models on its own data?
- BMS has external AI discovery agreements with Chai Discovery, Schrödinger, insitro and Evotec, has joined the OpenFold and Apheris federated initiatives, and is hiring its own machine learning and computational design staff. Who decides whether to license an external AI model or agentic tool rather than build on BMS's own models and compute, and does that decision pass through Computational Sciences, the digital and technology organisation, business development or procurement?
Coverage limits
BMS's newsroom blocked access, so releases were read from its investor relations feed, which leaves out some deal releases, and call transcripts were not retrieved. The SEC site, Business Wire and several trade titles also blocked access, so partner deals were read on partner sites and in trade press, and the date of the Schrödinger agreement is unknown. The search budget covered research labs and data less fully than AI in drug discovery, although a dedicated search on 8 October 2026 for lab automation, ELN, LIMS and scientific data platforms found no further eligible disclosure.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call